Bioleaders Corporation
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and… Read more
Bioleaders Corporation (142760) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.048x
Based on the latest financial reports, Bioleaders Corporation (142760) has a cash flow conversion efficiency ratio of -0.048x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.59 Billion) by net assets (₩33.09 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bioleaders Corporation - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Bioleaders Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bioleaders Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioleaders Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Akme Fintrade India Ltd
NSE:AFIL
|
-0.220x |
|
Alan Allman Associates SA
PA:AAA
|
0.275x |
|
FreeMs Corporation
KQ:053160
|
0.004x |
|
Resilient Property Income Fund Ltd
JSE:RES
|
0.031x |
|
T2 Metals Corp.
V:TWO
|
-0.077x |
|
Viscom AG
XETRA:V6C
|
0.005x |
|
United Maritime Corporation
NASDAQ:USEA
|
-0.012x |
|
Blue Square Real Estate Ltd
TA:BLSR
|
0.037x |
Annual Cash Flow Conversion Efficiency for Bioleaders Corporation (2015–2024)
The table below shows the annual cash flow conversion efficiency of Bioleaders Corporation from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩37.31 Billion | ₩-501.75 Million | -0.013x | -107.80% |
| 2023-12-31 | ₩35.79 Billion | ₩6.18 Billion | 0.173x | +118.16% |
| 2022-12-31 | ₩21.69 Billion | ₩-20.60 Billion | -0.950x | -751.07% |
| 2021-12-31 | ₩45.11 Billion | ₩-5.04 Billion | -0.112x | +37.04% |
| 2020-12-31 | ₩30.60 Billion | ₩-5.43 Billion | -0.177x | -92.34% |
| 2019-12-31 | ₩23.82 Billion | ₩-2.20 Billion | -0.092x | +75.30% |
| 2018-12-31 | ₩23.50 Billion | ₩-8.77 Billion | -0.373x | -53.95% |
| 2017-12-31 | ₩35.17 Billion | ₩-8.53 Billion | -0.242x | +45.00% |
| 2016-12-31 | ₩17.46 Billion | ₩-7.70 Billion | -0.441x | +49.32% |
| 2015-12-31 | ₩5.55 Billion | ₩-4.83 Billion | -0.870x | -- |